PMDD: When PMS Becomes a Burden for the Mind
Some women almost lose themselves in the second half of their cycle. Premenstrual dysphoric disorder is the severe form of premenstrual symptoms. It is real, it is described, and it can be treated. This article shows you how to recognise and make sense of it.
When a woman tells me that for one week a month she becomes a person she herself does not like, I do not hear "a bit of PMS". I hear a pattern that deserves a name. PMDD is not a character flaw and not an exaggeration. It is a hormonally triggered reaction of the brain to the entirely normal fluctuations of the cycle. Once you understand that, you stop blaming yourself and start acting in a focused way.
Perhaps you know the pattern. For two weeks you are resilient, balanced, yourself. Then, somewhere after ovulation, something tips over. Not a little, but fundamentally. Irritability turns into anger, sadness into despair, and you say things you later regret. With the period the knot often loosens within a day. You breathe a sigh of relief and think everything is fine again. Until the next time.
This very pattern is the hallmark of premenstrual dysphoric disorder, PMDD for short. In this article we clarify how PMDD differs from ordinary PMS, what is probably happening in the brain, how the diagnosis is made through a cycle diary, and which treatment paths exist today. Throughout, the three-step rhythm applies: first feel, then understand, then act.
PMS or PMDD: the same ground, a different scale
PMS and PMDD are not two separate worlds. They lie on one spectrum. Premenstrual syndrome is common, widespread and usually mild to moderate. Breast tenderness, irritability, a bloated belly, slightly thinner nerves in the days before the period. Annoying, but bearable for most women.
PMDD is the severe form, and for good reason it stands as a distinct diagnosis in the DSM-5, the classification system of mental disorders. The difference lies not only in intensity but in emphasis. With PMDD the emotional symptoms dominate: pronounced mood lability, strong irritability and anger, depressed mood with hopelessness, inner tension and anxiety. And above all: a clear impairment of daily life, work and relationships.
PMDD as a distinct diagnosis, about three to eight percent affected
Review Liisa Hantsoo and C. Neill Epperson classified PMDD in 2015 in Current Psychiatry Reports as a distinct disorder of the DSM-5. Its profile of cognitive-affective symptoms in the premenstrual window differs from other affective disorders through its cyclical character. The authors describe neurosteroids as a central contributor to its development. Frequency figures in the literature mostly lie in the range of about three to eight percent of women of reproductive age. A review from Dresden (Haußmann 2024, Der Nervenarzt) gives around two percent for the more strictly defined PMDD.
Hantsoo L, Epperson CN. Curr Psychiatry Rep. 2015;17(11):87. doi:10.1007/s11920-015-0628-3 · PMID: 26377947 · Haußmann J et al. Nervenarzt. 2024;95(3):268-274. doi:10.1007/s00115-024-01625-5 · PMID: 38393358
What matters is the timing, the choreography. The symptoms appear in the second half of the cycle, the so-called luteal phase, and they ease quickly once bleeding starts. After that, a symptom-free phase follows. This flaring and fading is the decisive difference from a continuous depression, which knows no such rhythm. And now you know why the question "when exactly" matters so much with premenstrual symptoms.
PMDD is not "especially bad PMS that is your own fault". It is a distinct, well-described disorder at the interface of hormone and brain. The emotional symptoms are not a sign of weakness. They are the tangible consequence of an altered reaction of your nervous system to entirely normal hormone fluctuations.
What happens in the brain: allopregnanolone and the GABA system
This is where it gets interesting, because the research of recent years has changed the picture. For a long time people searched for a too-much or too-little of a hormone. Yet in women with PMDD the hormone levels themselves are usually unremarkable. The key lies not in the amount but in the sensitivity of the brain to the normal fluctuations.
At the centre stands allopregnanolone, a metabolite of progesterone. After ovulation, progesterone rises, and with it allopregnanolone. This substance acts on the GABA system, the most important calming switchboard in the brain. Normally allopregnanolone dampens, much like the body's own sedative. In sensitive women, however, the response of the GABA system appears altered, so that this very calming substance can, in the luteal phase, trigger tension, irritability and low moods.
Altered sensitivity to allopregnanolone in PMDD
Comparative study, n=20 Erika Timby and colleagues, in 2016 in Psychopharmacology, gave allopregnanolone directly into the vein to ten women with PMDD and ten control women, once in the first and once in the second half of the cycle. Eye movement was measured as a marker of GABA system activity. Result: the response to allopregnanolone in women with PMDD was clearly different depending on cycle phase compared with the controls. The authors conclude that PMDD involves an altered sensitivity to allopregnanolone. This supports the idea that not the hormone level but the response to it is decisive.
Timby E, Bäckström T, Nyberg S, et al. Psychopharmacology (Berl). 2016;233(11):2109-2117. doi:10.1007/s00213-016-4258-1 · PMID: 26960697
This finding is supported by further work. Liisa Hantsoo and C. Neill Epperson described PMDD in 2020 in Neurobiology of Stress as a disorder of suboptimal sensitivity to neuroactive steroid hormones, with a disrupted interaction between allopregnanolone and the GABA receptor and a heightened stress sensitivity in the luteal phase (doi:10.1016/j.ynstr.2020.100213, PMID: 32435664). A recent review by Marie Bixo and colleagues in 2025 in the British Journal of Psychiatry describes allopregnanolone as a likely central provocateur in sensitive women (doi:10.1192/bjp.2025.103, PMID: 40518728). And now you know why "your hormones are normal" and "I feel terrible" can both be true.
"With PMDD the hormones must be out of balance, otherwise there would be no symptoms." In fact it is usually the other way around. Studies generally find normal hormone levels in women with PMDD. The difference lies in how sensitively the brain responds to the entirely normal cyclical fluctuation. A hormone test can therefore neither prove nor rule out PMDD.
The four PNI lenses on PMDD
In clinical psychoneuroimmunology, PNI for short, we look at a clinical picture not just at one organ but at four interwoven levels. With PMDD all four play together and explain why it has so many layers. Each lens illuminates one part at the cellular level.
Nervous system and GABA
This is the core. Allopregnanolone, the metabolite of progesterone, acts on the GABA-A receptor, the calming system in the brain. In PMDD the sensitivity of this receptor to the cyclical fluctuations appears altered. A rapid drop or an altered response to allopregnanolone can weaken the inhibitory action of GABA neurons and thereby raise excitability. This could help explain irritability, anxiety and mood lability.
Stress system and HPA axis
Women with PMDD often respond more sensitively to stress in the luteal phase. Research suggests that the control of the stress axis through allopregnanolone and GABA works less well in PMDD. So the same everyday stress can hit much harder in the second half of the cycle. This is not a lack of discipline but a neurobiological shift of the threshold of tolerance.
Serotonin and messengers
The serotonin system is in close interaction with the sex hormones. This is exactly where serotonin reuptake inhibitors act, which in PMDD can often work within a short time, unlike in classical depression. This suggests that serotonin transmission is involved in the emergence of the symptoms and offers an important point of leverage.
Predisposition and sensitivity
Not every woman responds the same way to the same hormone fluctuations. Studies point to an inherited component and to differences in cellular sensitivity to sex hormones. PMDD is thus less a question of the amount of hormones than of the individual readiness of the system to react. This explains why one woman barely notices anything and another suffers greatly.
These four lenses show why with PMDD there is no single adjusting screw. They also explain why very different approaches can help, from medication at the serotonin or GABA system to stress regulation and sleep. And now you know why good treatment is more than just a prescription.
Diagnosis: why the cycle diary decides everything
Here lies perhaps the most important practical point. PMDD cannot be proven through a blood test. The diagnosis hinges on the pattern, and the pattern only becomes visible through a prospective cycle diary. Prospective means: you record the symptoms daily, while they are happening, not afterwards from memory.
That sounds laborious, but it is the heart of the matter. Looking-back estimates often deceive. Whoever is asked during the bad phase remembers the good days less well. Only a diary over at least two consecutive cycles reliably shows whether the symptoms really are tied to the luteal phase and clearly ease after the period.
Standardised diagnosis through daily symptom records
Validation study, n=200 Tory Eisenlohr-Moul and colleagues, in 2017 in the American Journal of Psychiatry, developed a standardised system to reliably derive the DSM-5 criteria of PMDD from daily symptom ratings. Two hundred women kept a daily record over two to four months using the Daily Record of Severity of Problems. The system agreed about 98 percent of the time with the assessment of experienced clinicians. A central observation: looking-back self-reports predicted the prospectively confirmed diagnosis only poorly. This underlines why daily recording is indispensable.
Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, et al. Am J Psychiatry. 2017;174(1):51-59. doi:10.1176/appi.ajp.2016.15121510 · PMID: 27523500
By the DSM-5 criteria, at least five distressing symptoms in the luteal phase are needed, at least one of them in the affective domain such as mood lability, irritability, depressed mood or tension. It is also important to distinguish another mental illness. If a depression or anxiety disorder persists all year round and merely worsens premenstrually, this is called premenstrual exacerbation, not PMDD. The diary makes this visible too. And now you know why the first step is not the laboratory but the pen.
Treatment options: what the evidence offers today
The good news first. PMDD is one of the best-studied cycle-bound disorders, and several effective paths exist. Which one fits depends on severity, life situation and family planning, and always belongs in medical hands. I describe directions here, not recipes.
Best documented is treatment with serotonin reuptake inhibitors, SSRIs for short. The remarkable thing: in PMDD they can often work within hours to days, not only after weeks as in depression. This is a hint that a different mechanism is at play here. They can be taken continuously or only in the second half of the cycle.
SSRI only in the symptomatic phase
RCT, n=252 Kimberly Yonkers and colleagues examined in 2015 in JAMA Psychiatry whether sertraline still shows an effect when it is taken only from the onset of symptoms until the first few days of the period. 252 women with PMDD took either sertraline or placebo over six cycles. In the active group several symptom scales improved more strongly, especially tension and irritability, and more women responded to the treatment. The authors note that the effect varies in clarity depending on the symptom scale. Notably, stopping was not associated with withdrawal symptoms.
Yonkers KA, Kornstein SG, Gueorguieva R, et al. JAMA Psychiatry. 2015;72(10):1037-1044. doi:10.1001/jamapsychiatry.2015.1472 · PMID: 26351969
The second major path is hormonal. Certain combined pills with a shortened or absent break can smooth the strong hormone fluctuation by suppressing ovulation. In severe, treatment-resistant cases further options such as GnRH agonists with hormonal add-back come into consideration. A medical review by Kimberly Yonkers and Michael Simoni in 2017 in the American Journal of Obstetrics and Gynecology names SSRIs and certain hormonal contraceptives as the most effective approaches (doi:10.1016/j.ajog.2017.05.045, PMID: 28571724).
Non-medication paths also have their place. For cognitive behavioural therapy there is increasing evidence that it can reduce the burden.
Internet-based behavioural therapy in PMDD
RCT, n=174 Cornelia Weise and colleagues investigated in 2019 in Psychotherapy and Psychosomatics an eight-week, therapist-guided internet-based cognitive behavioural therapy in 174 women with PMDD. Compared with a waiting list, functional and psychological impairment, the impact on daily life and symptom intensity improved clearly. The effects remained stable up to six months after treatment. The authors highlight that active coping strategies and stress management played a particular role. An older systematic review (Lustyk 2009) still urged caution here, as the evidence base was thin at the time.
Weise C, Kaiser G, Janda C, et al. Psychother Psychosom. 2019;88(1):16-29. doi:10.1159/000496237 · PMID: 30783069 · Lustyk MKB et al. Arch Womens Ment Health. 2009;12(2):85-96. doi:10.1007/s00737-009-0052-y · PMID: 19247573
What matters is the honest framing. Conventional treatment with SSRIs and hormonal approaches is well documented and a genuine gain for many women. What an integrative view can add is a look at the foundations: sleep, movement, stress regulation and knowing your own cycle. These factors do not replace treatment, but they can sensibly support it. And now you know that no one has to endure these symptoms untreated.
Three levers that can prepare the ground
Before we talk about medication, it is worth looking at the foundations. They do not replace medical treatment, but they can relieve the system and ease the diagnosis. These three levers are a starting point, not a treatment plan.
Keep a prospective cycle diary
This is the most important step you can take yourself. Over at least two cycles, record daily how strong your symptoms are. It makes the pattern visible, eases the diagnosis and shows you yourself that the symptoms are cycle-bound and ease again. Even this knowledge can be a relief and takes the unpredictability out of the whole thing.
Protect sleep and nervous system in the second half of the cycle
Because stress sensitivity can rise in the luteal phase, a stable sleep rhythm matters especially here. Regular movement and deliberate recovery windows can relieve the nervous system. Some women benefit from deliberately not scheduling demanding commitments during the critical days. That is not weakness but smart planning along your own rhythm.
Seek medical support rather than carrying it alone
PMDD can be treated, but choosing the right path needs expertise. If the symptoms clearly impair your daily life, your relationships or your work, that belongs in medical hands. A good assessment takes your symptoms seriously, distinguishes other causes and finds the fitting approach together with you. You do not have to solve this alone.
You are not your worst day of the cycle
PMDD does not turn you into a different person. It is a cyclical reaction of your brain to normal hormone fluctuations, and it has a name, an explanation and treatment paths. When you recognise the pattern and take it seriously, you give yourself the chance to stop letting the good two weeks be overshadowed by the fear of the hard days.
Frequently asked questions about PMDD
What is the difference between PMS and PMDD?
PMS and PMDD sit on the same spectrum but differ in severity and emphasis. Premenstrual syndrome (PMS) is common and usually mild to moderate, with physical and emotional symptoms in the days before the period. Premenstrual dysphoric disorder (PMDD) is the severe form and is listed in the DSM-5 as a distinct diagnosis. The foreground is dominated by pronounced psychological symptoms: strong irritability, mood swings, depressed mood, inner tension and a sense of losing control. What matters is that the symptoms occur in the second half of the cycle, ease quickly once bleeding starts, and clearly impair daily life. About three to eight percent of women of reproductive age are affected.
What are the symptoms of PMDD?
PMDD shows up mainly through psychological symptoms in the luteal phase, that is the second half of the cycle. Typical features are pronounced mood lability, strong irritability or anger, depressed mood with hopelessness, and marked inner tension or anxiety. There are often concentration problems, exhaustion, altered sleep and eating, a sense of being overwhelmed, and physical symptoms such as breast tenderness, bloating and joint aches. The hallmark is the pattern: symptoms appear in a cycle-bound way, ease within a few days of the period starting, and a symptom-free phase follows. This flaring and fading is exactly what distinguishes PMDD from a continuous depression.
How is PMDD diagnosed?
The diagnosis of PMDD does not rest on a blood test but on a prospective cycle diary over at least two consecutive cycles. You record daily how strong your symptoms are. This makes it possible to check whether the symptoms really are tied to the second half of the cycle and clearly ease after the period. Looking-back estimates are not enough, because memory often deceives. An established tool is the Daily Record of Severity of Problems (DRSP). The DSM-5 criteria require at least five distressing symptoms in the luteal phase, at least one of them in the affective domain, with clear impairment of daily life. It is also important to rule out an underlying depression or anxiety disorder that merely worsens premenstrually.
What causes PMDD?
By current understanding, PMDD is not driven by an abnormal amount of hormones but by an altered sensitivity of the brain to the normal hormone fluctuations of the cycle. At the centre is allopregnanolone, a metabolite of progesterone that rises in the second half of the cycle. Allopregnanolone acts on the calming GABA system in the brain. In women with PMDD, the GABA system's response to these fluctuations appears altered, so that a substance that should be calming can instead trigger tension and irritability. The serotonin system also plays a part, and there are signs of an inherited component. The hormone levels themselves are usually unremarkable.
How can PMDD be treated?
For PMDD there are several evidence-based approaches that always belong in medical hands. Best documented is treatment with serotonin reuptake inhibitors (SSRIs), which, unlike in depression, can often work within hours to days and are taken either continuously or only in the second half of the cycle. Hormonal approaches such as certain combined pills with a shortened break may also help. For very severe courses, further options come into consideration. Alongside this, there are signs that cognitive behavioural therapy can reduce the burden. Lifestyle factors such as sleep, movement and stress regulation can support the foundation. Which path fits depends on severity, life situation and family planning.
Does the pill help with PMDD?
Certain combined hormonal contraceptives may help with PMDD, especially those with the progestin drospirenone and a shortened or absent hormone-free interval. The idea behind it: if ovulation is suppressed and the strong hormone fluctuation is smoothed, this can soften the trigger of the symptoms. The effect varies a great deal from person to person. Some women experience a clear improvement, others are sensitive to the synthetic hormones and feel worse on them. This is therefore not a blanket solution but an option that should be weighed up medically and observed over time. A prospective cycle diary helps to judge the effect honestly.
Is PMDD a mental illness or a hormone problem?
PMDD is both at once, and that is exactly what makes it so easy to misunderstand. It is listed in the DSM-5 as a depressive disorder, that is a psychiatric diagnosis. Its trigger, however, is hormonal: the cyclical fluctuation of progesterone and its metabolite allopregnanolone. A more fitting image is that of a hormonally triggered neurobiological reaction. The brain of women with PMDD responds more sensitively to normal hormone fluctuations. PMDD is therefore not a character weakness and not a mere low mood that you can simply train yourself out of. It is a real, well-described disorder at the interface of hormone and brain that should be taken seriously and treated.
Does PMDD disappear in menopause?
Because PMDD is tied to ovulation and the cyclical hormone fluctuation, it usually fades after menopause, when the cycle ends for good. The path there, however, is often not straightforward. In perimenopause, the years before the last period, hormones fluctuate especially strongly and unpredictably. This can at times even intensify premenstrual symptoms before they ease. A pregnancy or breastfeeding also interrupts the cycle and with it often the symptoms. What matters: many years can pass before menopause. No one has to endure that time untreated, because effective options exist.
What can I do myself about PMDD?
Self-help does not replace treatment but can support the foundation. A prospective cycle diary is the most important first step, because it makes patterns visible and eases the diagnosis. A stable sleep rhythm, regular movement and deliberate stress regulation in the second half of the cycle can help to relieve the nervous system. Some women benefit from deliberately not scheduling demanding commitments during the critical days. Simply knowing that the symptoms are cycle-bound and will ease again can be a relief. With pronounced symptoms, especially with depressive despair, the whole thing belongs in medical hands rather than being carried alone.
When should I see a doctor about PMDD?
If premenstrual symptoms clearly impair your daily life, your relationships or your work, that belongs in medical assessment rather than being dismissed as normal. This is especially true when the emotional symptoms dominate. You should seek urgent medical assessment for severe low moods, pronounced hopelessness, or the impression of regularly losing control in the second half of the cycle. Behind premenstrual symptoms there can also be another treatable cause, such as a depression or anxiety disorder that worsens cyclically. If you have thoughts of no longer wanting to live, please seek help immediately, for example through a free crisis helpline.
All topics in the cluster "Hormone Guide"
This spoke belongs to the bigger picture of female hormones. Each topic illuminates one part of the connected system.
- Hormonal Imbalance in Women (overview/pillar)
- Estrogen Dominance: recognising symptoms and addressing them naturally
- Xenoestrogens: hormone disruptors in everyday life
- Coming off the pill: what happens in the body
- Progesterone deficiency: symptoms and testing
- PMS: symptoms and what can help
- PMDD: when PMS reaches the mind
- Perimenopause: symptoms and from when
- Menopause: symptoms and what can help
- PCOS: causes and symptoms
- Hormonal acne from within
- Endometriosis: an integrative view
- Hormone-free contraception compared
- Loss of libido in women
- Testing hormones: which test, when
- Lowering estrogen naturally (liver)
- Cycle-based nutrition
- The thyroid and female hormones
- Insulin resistance and hormones
- Cortisol, stress and female hormones
- Chasteberry and herbal hormone helpers
Connections to other topics
Because stress sensitivity can rise in the luteal phase, it is worth looking at the stress hormone cortisol and the axis that steers it.
A borderline thyroid can influence mood, drive and cycle and intensify premenstrual symptoms.
Iron deficiency can intensify exhaustion and low moods, which become especially noticeable around the period.
Through the immune system and estrogen metabolism, the gut can help determine how balanced the hormone household stays.
Sources and further reading
- Hantsoo L, Epperson CN. Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Curr Psychiatry Rep. 2015;17(11):87. doi:10.1007/s11920-015-0628-3 · PMID: 26377947 [Review]
- Haußmann J, Goeckenjan M, Haußmann R, Wimberger P. Premenstrual syndrome and premenstrual dysphoric disorder. Nervenarzt. 2024;95(3):268-274. doi:10.1007/s00115-024-01625-5 · PMID: 38393358 [Review]
- Timby E, Bäckström T, Nyberg S, et al. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls. Psychopharmacology (Berl). 2016;233(11):2109-2117. doi:10.1007/s00213-016-4258-1 · PMID: 26960697 [Comparative study, n=20]
- Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids. Neurobiol Stress. 2020;12:100213. doi:10.1016/j.ynstr.2020.100213 · PMID: 32435664 [Mechanism Review]
- Bixo M, Stiernman L, Bäckström T. Neurosteroids and premenstrual dysphoric disorder. Br J Psychiatry. 2025;1-9. doi:10.1192/bjp.2025.103 · PMID: 40518728 [Review]
- Sikes-Keilp C, Rubinow DR. GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder. CNS Drugs. 2023;37(8):679-693. doi:10.1007/s40263-023-01030-7 · PMID: 37542704 [Review]
- Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA. Neurosci Biobehav Rev. 2023;149:105168. doi:10.1016/j.neubiorev.2023.105168 · PMID: 37059403 [Review]
- Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, et al. Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry. 2017;174(1):51-59. doi:10.1176/appi.ajp.2016.15121510 · PMID: 27523500 [Validation study, n=200]
- Yonkers KA, Kornstein SG, Gueorguieva R, et al. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(10):1037-1044. doi:10.1001/jamapsychiatry.2015.1472 · PMID: 26351969 [RCT, n=252]
- Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2017;218(1):68-74. doi:10.1016/j.ajog.2017.05.045 · PMID: 28571724 [Review]
- Weise C, Kaiser G, Janda C, et al. Internet-Based Cognitive-Behavioural Intervention for Women with Premenstrual Dysphoric Disorder: A Randomized Controlled Trial. Psychother Psychosom. 2019;88(1):16-29. doi:10.1159/000496237 · PMID: 30783069 [RCT, n=174]
- Lustyk MKB, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009;12(2):85-96. doi:10.1007/s00737-009-0052-y · PMID: 19247573 [Systematic Review]
- de Carvalho AB, Cardoso TA, Mondin TC, et al. Prevalence and factors associated with Premenstrual Dysphoric Disorder: A community sample of young adult women. Psychiatry Res. 2018;268:42-45. doi:10.1016/j.psychres.2018.06.005 · PMID: 29986177 [Cohort]